Observing treatment experiences with foslevodopa/foscarbidopa in advanced Parkinson's disease
Observational Retrospective CoHort Study on Practical ExperienceS of Treatment With Foslevodopa/foScaRbidopa in Advanced Parkinson's Disease
This study is looking at how patients with advanced Parkinson's disease feel while using a new treatment called foslevodopa/foscarbidopa through a pump to see how it works in real-life settings.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | AbbVie Industry-sponsored |
| Locations | 4 sites (Graz, Styria and 3 other locations) |
| Trial ID | NCT06937034 on ClinicalTrials.gov |
What this trial studies
This study aims to document the experiences of patients with advanced Parkinson's disease who are receiving subcutaneous infusion of foslevodopa/foscarbidopa. It focuses on the evolution of infusion settings, including base, high, and low infusion rates, at various time points during treatment. The data will be collected through the ONE-CRM system, providing insights into the practical application of this therapy in routine clinical practice.
Who should consider this trial
Good fit: Ideal candidates are individuals diagnosed with levodopa-responsive idiopathic Parkinson's disease who are currently prescribed foslevodopa/foscarbidopa.
Not a fit: Patients who are not diagnosed with levodopa-responsive idiopathic Parkinson's disease or those not receiving foslevodopa/foscarbidopa will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of optimal infusion strategies for managing advanced Parkinson's disease.
How similar studies have performed: While this study focuses on practical experiences, similar approaches in managing Parkinson's disease have shown promise, indicating potential for beneficial outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: \- Diagnosed with levodopa-responsive idiopathic Parkinson's Disease prescribed on LDp/CDp CSCI in routine clinical practice who have consented to be enrolled in the AbbVie Patient Support Program.
Where this trial is running
Graz, Styria and 3 other locations
- Medizinische Universitaet Graz /ID# 278569 — Graz, Styria, Austria (Not_yet_recruiting)
- Medisch Spectrum Twente /ID# 276695 — Enschede, Overijssel, Netherlands (Recruiting)
- Universitatea De Medicină Și Farmacie Victor Babeș /ID# 276720 — Timișoara, Timiș County, Romania (Recruiting)
- Karolinska University Hospital Solna /ID# 277116 — Solna, Stockholm County, Sweden (Recruiting)
Study contacts
- Study coordinator: Abbvie Call Center
- Email: abbvieclinicaltrials@abbvie.com
- Phone: 844-663-3742
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.